Clinical Trial Update: Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating suvorexant (Belsomra) to prevent delirium in hospitalized cancer patients with insomnia has been withdrawn. Sponsor: Mayo Clinic.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Delirium
• Insomnia

Drugs mentioned

• Belsomra (suvorexant)

Snippet

Sponsor: Mayo Clinic | Conditions: Advanced Malignant Solid Neoplasm, Delirium | Phase 4 | Status: WITHDRAWN